Eli Lilly is named among the drugmakers leading the GLP-1 market as a new fund covers a wider peptide field. The article cites growing demand but reports no new Lilly sales or business change, so Lilly's outlook is unchanged.
The report points to growth in peptide-based treatments, but gives no new sales, supply, or company plans for Lilly. The fund also spreads investment across 36 businesses and several parts of the field. The story does not change Lilly's business outlook.
Novo Nordisk is named among the drugmakers leading the GLP-1 market as a new fund covers a wider peptide field. The article cites growing demand but reports no new Novo sales or business change, so Novo's outlook is unchanged.
Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for LLY